LLY Sep 2024 300.000 put
| Previous close | 0.2600 |
| Open | 0.2600 |
| Bid | 0.0000 |
| Ask | 0.9500 |
| Strike | 300.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.2600 - 0.2600 |
| Contract range | N/A |
| Volume | |
| Open interest | 84 |
- Yahoo Finance Video
Weight-loss drug competition heats up. Is Wegovy in trouble?
The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments made by Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen — Novo Nordisk makes Wegovy and Ozempic — and Eli Lilly (LLY) CEO Dave Ricks — Eli Lilly makes Zepbound and Mounjaro — to Yahoo Finance over the past several months. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
ZacksAmgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
ZacksPharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
